OptiBiotix Health PLC Approval of GoFigure products
October 24 2022 - 2:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
24 October 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
Approval of GoFigure products with Saudi Food and Drug
Authority
OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d
eveloping compounds to tackle obesity, cardiovascular disease and
diabetes , announces its exclusive distributor Nahdi Medical Co
("Nahdi") has received approval from the Saudi Food and Drug
authority (" SFDA") for GoFigure shakes and bars containing
patented weight management aid SlimBiome(R).
The Company announced it had signed an exclusive sales and
marketing agreement with Nahdi in December 2021. Nahdi owns the
largest pharmacy network in the Kingdom of Saudi Arabia ("KSA")
with over 1,100 pharmacy outlets countrywide. Nahdi's online
platform, Nahdi Online, is one of the leading e-commerce pharmacy
players across the six countries of the Gulf Cooperation Council
("GCC") https://www.nahdionline.com/en/ .
The SFDA approval originally envisaged for early 2022, is a
critical milestone on the way to marketing and selling the GoFigure
range of products through the pharmacies of Nahdi in Saudi Arabia.
The SFDA approval is of strategic importance to both Nahdi and
OptiBiotix as it facilitates the registration processes in the
other GCC countries ( Bahrain , Kuwait , Oman , Qatar and the
United Arab Emirates ) .
As a direct consequence, OptiBiotix has received the first
purchase order from Nahdi. The manufacturing of the range of
products has commenced and the launch envisaged for Q1 2023 is in
full preparation. The initial launch is planned to take place in
strategically key locations within Saudi Arabia and through Nahdi's
e-commerce platform.
GoFigure is OptiBiotix' direct-to-consumer (D2C) range of weight
management products formulated with core ingredient SlimBiome(R).
The GoFigure range of products consists of powdered meal
replacement & beverage products (shakes, smoothies, pancake
mixes, etc) and healthy snacking (crisps, puffs, gummies,
etc.).
SlimBiome(R) is a patented prebiotic weight management aid used
as such or in formulated products in the health & wellness,
sports nutrition and weight management categories. SlimBiome (R) is
supported by independent human clinical studies which show it
reduces hunger, cravings for sweet and savoury foods and fat
intake, and helps people stick to a low calorie diet plan.
Consumers who used SlimBiome (R) in combination with a calorie
restricted diet experience a relief from feeling hungry and have
fewer cravings for food, leading to easier and more sustainable
dieting and lose on average an additional 2kg of fat per month,
improving body composition.
René Kamminga, C EO of O pti B i oti x Limited, a wholly owned
subsidiary of OptiBiotix Health plc, c o m mented: "I am very
pleased the regulatory approval process is now complete and that we
can now focus on getting the GoFigure range direct to the Saudi
consumer. The GoFigure range has been specifically formulated to
support consumers aiming to reduce their weight, help them stick to
their change in diet and improve their gut microbiome at the same
time. This particular range has been adapted specifically to fit
the consumer preferences in Saudi Arabia and we are confident that
we can build lasting success with our partner Nahdi."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGZMZGKMNGZZM
(END) Dow Jones Newswires
October 24, 2022 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024